- Home
- LFMD vs XOMAP Comparison
LFMD vs XOMAP Comparison
Compare LFMD & XOMAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LFMD
- XOMAP
- Stock Information
- Founded
- LFMD 1994
- XOMAP N/A
- Country
- LFMD United States
- XOMAP United States
- Employees
- LFMD N/A
- XOMAP 13
- Industry
- LFMD Medical/Nursing Services
- XOMAP Biotechnology: Pharmaceutical Preparations
- Sector
- LFMD Health Care
- XOMAP Health Care
- Exchange
- LFMD Nasdaq
- XOMAP Nasdaq
- Market Cap
- LFMD N/A
- XOMAP N/A
- IPO Year
- LFMD N/A
- XOMAP N/A
- Fundamental
- Price
- LFMD $4.58
- XOMAP $26.44
- Analyst Decision
- LFMD Strong Buy
- XOMAP
- Analyst Count
- LFMD 6
- XOMAP 0
- Target Price
- LFMD $13.00
- XOMAP N/A
- AVG Volume (30 Days)
- LFMD 546.6K
- XOMAP N/A
- Earning Date
- LFMD 11-06-2024
- XOMAP N/A
- Dividend Yield
- LFMD N/A
- XOMAP N/A
- EPS Growth
- LFMD N/A
- XOMAP N/A
- EPS
- LFMD N/A
- XOMAP N/A
- Revenue
- LFMD $178,279,867.00
- XOMAP N/A
- Revenue This Year
- LFMD $37.74
- XOMAP N/A
- Revenue Next Year
- LFMD $24.21
- XOMAP N/A
- P/E Ratio
- LFMD N/A
- XOMAP N/A
- Revenue Growth
- LFMD 38.63
- XOMAP N/A
- 52 Week Low
- LFMD $4.10
- XOMAP N/A
- 52 Week High
- LFMD $12.88
- XOMAP N/A
- Technical
- Relative Strength Index (RSI)
- LFMD 43.02
- XOMAP 64.80
- Support Level
- LFMD $4.10
- XOMAP $25.90
- Resistance Level
- LFMD $4.91
- XOMAP $26.13
- Average True Range (ATR)
- LFMD 0.30
- XOMAP 0.16
- MACD
- LFMD 0.00
- XOMAP 0.04
- Stochastic Oscillator
- LFMD 38.40
- XOMAP 100.00
About XOMAP XOMA Corporation 8.625% Series A Cumulative Perpetual Preferred Stock
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.